A study of the relationship between neurological function and serum vitamin E concentrations in patients with cystic fibrosis

HJ WILLISON,* DPR MULLER,† S MATTHEWS,† S JONES,‡ A KRIS,‡ RJ STEAD,* ME HODSON,* AE HARDING‡

From Brompton Hospital and the Cardiothoracic Institute,* the Institute of Child Health, † and the Institute of Neurology,‡ London, UK

SUMMARY A patient with cystic fibrosis and undetectable serum vitamin E concentrations is described who developed a progressive spino-cerebellar syndrome and pigmentary retinopathy with abnormal somatosensory and visual evoked potentials (SSEPs and VEPs). In order to assess the relationship between neurological function and serum vitamin E concentrations in cystic fibrosis, 29 unselected patients who had no neurological symptoms were examined neurologically. Ten were randomly selected for neurophysiological assessment by recording SSEPs and VEPs. Electroretinograms (ERGs) were also performed in five cases. The findings were correlated with serum vitamin E concentrations which were unknown to the neurologists prior to completion of the study. Only one patient had definite reflex and sensory abnormalities, and the remaining 28 were clinically normal. The ERG was abnormal in two cases, one of whom had abnormal VEPs. SSEPs were normal in all 10 cases. Twenty-six patients had serum vitamin E concentrations below the normal range. In two of the three patients who had definite neurological or electrophysiological abnormalities serum vitamin E concentrations were below the median value for the whole group.

Severe vitamin E deficiency as a consequence of prolonged fat malabsorption is now a well-established cause of a progressive neurological disorder comprising ataxia, areflexia, and proprioceptive loss. This syndrome is particularly prevalent in children with abetalipoproteinaemia and chronic liver disease.1 It has also been reported after extensive ileal resection2 and in a few cases of cystic fibrosis.3–4 Pathological studies in man5 and experimental animals6 have shown that vitamin E deficiency produces a dying-back neuropathy in sensory neurons which affects the centrally directed fibres in the posterior columns more severely than the peripheral axons. Mild degenerative changes also occur in the spinocerebellar tracts.7 Reduced serum concentrations of vitamin E are common in patients with cystic fibrosis, but it is not clear how often these are of clinical or pathological significance. This paper describes a patient with undetectable serum vitamin E concentrations who developed a spino-cerebellar syndrome and a pigmentary retinopathy. The results of a study correlating vitamin E status with clinical and neurophysiological observations in 29 neurologically asymptomatic cases of cystic fibrosis are also reported.

Case report

A 22-year-old woman with cystic fibrosis presented with meconium ileus in infancy. She had steatorrhoea and recurrent chest infections throughout childhood, and a number of episodes of jaundice before the age of five. Hepatomegaly was first noted when she was 12, and on investigation it appeared that her liver disease resulted from chronic active hepatitis. At the age of 14 yr she complained of night blindness and was found to have a pigmentary retinopathy. This was attributed to a documented severe deficiency of vitamin A but her symptoms progressed despite replacement therapy. Serum vitamin A concentrations increased but remained below the normal
pattern fibrosis.

Fig 1 Visual evoked potentials and electroretinograms to pattern reversal and flash in 22-year-old patient with cystic fibrosis. The occipital responses to pattern reversal are delayed and electroretinograms to both pattern and flash stimulation are severely degraded.

range (>20) at around 12 µg/100 ml. Four years later she became aware of progressive unsteadiness of gait, and at the age of 20 she developed clumsiness of the hands and slurring of speech. On examination she was thin with clubbed fingers and signs of chronic chest disease and hepatosplenomegaly. Visual acuity was 6/18 bilaterally, with absent colour vision, constricted visual fields and impaired dark adaptation. Fundoscopy showed extensive atrophy of the retinal pigment epithelium with fine pigment migration. There was bilateral ptosis, anisocoria, abnormal horizontal and vertical eye movements, and first degree nystagmus on lateral gaze. She had a cerebellar dysarthria and clumsy tongue movements. There was weakness of ankle and toe dorsiflexion, and ataxia of all four limbs with areflexia and flexor plantar responses. Proprioception, vibration sense, light touch appreciation and two point discrimination were impaired distally, more in the legs than the arms. She had a broad based ataxic gait with bilateral foot drop.

A full blood count was normal and no acanthocytes were present. Serum vitamin B12 and folate were normal. Total bilirubin was 29 µmol/l (normal <17); the hepatic enzymes were elevated (alkaline phosphatase 2247 iu/l, SGOT 163 iu/l and gamma GT 309 iu/l; normal <300, 35 and 33 respectively). A fasting blood glucose was marginally high at 7-5 mmol/l (normal <6-0). Serum cholesterol was normal at 3·2 µmol/l. Serum vitamin E was undetectable, but serum vitamin A was now in the normal range at 29 µg/100 ml. Cerebrospinal fluid examination and a CT brain scan were normal. Nerve conduction studies showed evidence of an axonal sensory neuropathy. VEPs were bilaterally delayed and degraded with P100 latencies of 127 (left eye) and 133 ms (right eye) (fig 1). The ERG was not detectable from either eye following pattern reversal and was very degraded following flash stimulation. SSEPs recorded over the clavicle (N9) and cervical spine (N13) following median nerve stimulation at the wrist were of marginally low amplitude but normal latency; over the sensory cortex the initial response (N20) was markedly delayed at 25-3 ms (fig 2). Brain stem auditory evoked potentials (BAEPs) were normal.

Treatment with oral and intramuscular vitamin E preparations was commenced in August 1983, but serum vitamin E concentrations were within the normal range for only two months before she was admitted to hospital with intermittent intestinal obstruction. She required hospitalisation for four months because of recurrent intra-abdominal sepsis, deterioration in liver function, and gastrointestinal bleeding. During her admission vitamin E supplements were withdrawn and her vision deteriorated. She remained weak and generally unwell until July 1984 but has subsequently improved slowly. Oral and intramuscular vitamin E supplements were reintroduced in May 1984.

On examination in February 1985 she had marked jaundice. Visual acuity was 6/24 on the right and 3/60 on the left, with severe constriction of the visual fields. Apart from more extensive loss of pain and touch appreciation below the knees the neurological examination had not changed significantly since July 1983. Her gait was ataxic and uncertain but this was clearly partly related to her visual loss. Serum vitamin E concentration was 23-8 µmol/l (normal 11-5–35).

Patients and methods

Patients with cystic fibrosis admitted to the Brompton Hospital, London, were investigated. They were included in the study if they were not known to have any neurological symptoms, had not received vitamin E supplements, had normal serum concentrations of vitamin B12 and folate, and had either normal or only mildly impaired glu-
Neurological function in cystic fibrosis

Table  Serum vitamin E and vitamin A concentrations and vitamin E/cholesterol ratios in patients with cystic fibrosis

<table>
<thead>
<tr>
<th>Case no</th>
<th>Vitamin E (μmol/l)</th>
<th>Vitamin E/cholesterol (μmol/mmol)</th>
<th>Vitamin A (μg/100ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1†</td>
<td>0.18</td>
<td>0.05</td>
<td>14</td>
</tr>
<tr>
<td>2*</td>
<td>3.4</td>
<td>1.06</td>
<td>28</td>
</tr>
<tr>
<td>3</td>
<td>3.4</td>
<td>1.17</td>
<td>29</td>
</tr>
<tr>
<td>4</td>
<td>0</td>
<td>0</td>
<td>29</td>
</tr>
<tr>
<td>5</td>
<td>3.5</td>
<td>1.18</td>
<td>21</td>
</tr>
<tr>
<td>6</td>
<td>4.0</td>
<td>1.05</td>
<td>23</td>
</tr>
<tr>
<td>7</td>
<td>5.1</td>
<td>1.96</td>
<td>33</td>
</tr>
<tr>
<td>8*</td>
<td>6.0</td>
<td>1.42</td>
<td>20</td>
</tr>
<tr>
<td>9</td>
<td>3.9</td>
<td>—</td>
<td>23</td>
</tr>
<tr>
<td>10</td>
<td>5.0</td>
<td>0.96</td>
<td>17</td>
</tr>
<tr>
<td>11</td>
<td>9.5</td>
<td>2.25</td>
<td>—</td>
</tr>
<tr>
<td>12</td>
<td>8.1</td>
<td>3.01</td>
<td>—</td>
</tr>
<tr>
<td>13</td>
<td>4.7</td>
<td>1.49</td>
<td>—</td>
</tr>
<tr>
<td>14</td>
<td>0</td>
<td>0</td>
<td>—</td>
</tr>
<tr>
<td>15</td>
<td>8.2</td>
<td>1.87</td>
<td>—</td>
</tr>
<tr>
<td>16</td>
<td>11.3</td>
<td>4.93</td>
<td>—</td>
</tr>
<tr>
<td>17</td>
<td>17.7</td>
<td>5.65</td>
<td>—</td>
</tr>
<tr>
<td>18</td>
<td>15.4</td>
<td>3.93</td>
<td>—</td>
</tr>
<tr>
<td>19</td>
<td>3.8</td>
<td>0.96</td>
<td>—</td>
</tr>
<tr>
<td>20</td>
<td>1.9</td>
<td>0.73</td>
<td>—</td>
</tr>
<tr>
<td>21</td>
<td>0</td>
<td>0</td>
<td>—</td>
</tr>
<tr>
<td>22</td>
<td>0.8</td>
<td>0.19</td>
<td>—</td>
</tr>
<tr>
<td>23</td>
<td>6.6</td>
<td>1.61</td>
<td>—</td>
</tr>
<tr>
<td>24</td>
<td>12.3</td>
<td>2.38</td>
<td>—</td>
</tr>
<tr>
<td>25</td>
<td>4.4</td>
<td>1.53</td>
<td>—</td>
</tr>
<tr>
<td>26</td>
<td>0</td>
<td>0</td>
<td>—</td>
</tr>
<tr>
<td>27</td>
<td>2.8</td>
<td>1.23</td>
<td>—</td>
</tr>
<tr>
<td>28</td>
<td>3.7</td>
<td>1.85</td>
<td>—</td>
</tr>
<tr>
<td>29</td>
<td>3.5</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

(normal range 11.5–35.0, mean ± 2 SD)

* = VEP and/or ERG abnormal, † = clinically abnormal, — = not measured.

cose tolerance. Those requiring hypoglycaemic drugs were excluded. Twenty nine patients were studied; their mean age was 24 (range 14–37) years. They were examined neurologically by either one or two of the authors (HJW and AEH), and their serum vitamin E concentrations were estimated colorimetrically. The vitamin E concentrations were unknown to the neurological investigators prior to completion of the study. Ten patients (Nos 1–10, table) were randomly selected for neurophysiological evaluation by means of visual, somatosensory, and brain stem auditory evoked potentials (BSAEPs), performed as previously described. Serum vitamin A concentrations were also measured in these 10 patients by high performance liquid chromatography. Electretinograms from each eye were recorded in five cases using a skin electrode on the lower eyelid referred to another on the outer canthus.

Results

Of the 29 patients investigated, serum vitamin E concentrations were reduced in 22 and undetectable in four, with a median value of 3.9 μmol/l (reference range 11.5–35 μmol/l) (table). Vitamin E status was also assessed by expressing the serum vitamin E concentration relative to the total cholesterol concentration. If this ratio is used as an index of vitamin E deficiency, three patients who had serum vitamin E concentrations below the lower limit of normal had normal ratios. The opposite did not occur. Two patients had reduced serum vitamin A concentrations (table).

On neurological examination, only one patient was clearly abnormal, with depressed or absent tendon reflexes, mildly reduced proprioception at the toes and Rombergism. Peripheral sensory and motor nerve conduction studies were normal. His serum vitamin E concentration and vitamin E/cholesterol ratio were very low at 0.18 μmol/l and 0.05 respectively; he also had a markedly reduced serum vitamin A concentration.

In all 10 patients studied SSEPs to upper and lower limb stimulation and BSAEPs were normal compared to age and sex matched controls studied in the same laboratory. There was no correlation between latency or amplitude of any of the SSEP components and serum vitamin E concentrations. Two of the five patients tested had bilaterally abnormal flash ERGs, with marked attenuation of the second (positive going 'b' wave) component. One of these had prolonged VEP latencies of 119–123 ms, 4–8 ms over the upper limit of normal. Both abnormal cases had reduced serum vitamin E concentrations and vitamin E/cholesterol ratios, but normal vitamin A concentrations (table). There was no correlation between VEP amplitude or latency and serum vitamin A or vitamin E concentrations in the 10 patients investigated.

Discussion

The neurological disorder observed in the patient described in the case report, which consisted of ataxia, areflexia, loss of joint position and vibration sense, ptosis and ophthalmpoplegia, is similar to that previously described in vitamin E deficiency associ-
ated with chronic fat malabsorption.\(^1\) Pigment-
tary retinopathy is common in untreated abetalipoproteinaemia and has been reported in a small
number of patients with other fat malabsorptive
syndromes.\(^3\)\(^4\)\(^5\)

Overt neurological disease associated with vita-
mn E deficiency is relatively rare in cystic fibrosis. Its occurrence has only previously been reported in
detail in three cases.\(^6\)\(^7\)\(^8\) The patient with cystic
fibrosis described here had severe liver disease
which gives rise to reduced luminal bile salt concen-
trations and therefore impaired solubilisation and
absorption of vitamin E.\(^9\) It is of interest that one of
the other reported cases of cystic fibrosis with a
spinocerebellar syndrome had had multiple ileal
resections\(^9\) which would result in reduced reabsorp-
tion and increased excretion of bile salts and a
reduction in size of the bile salt pool. The luminal
concentration of bile salts in another patient\(^4\) was
below the critical micellar concentration.

Detailed clinical assessment of 29 unselected
patients with cystic fibrosis showed definite
neurological abnormalities in only one. Most
patients had symptomatic steatorrhoea (range 0.9–
39 g faecal fat/day) which was controlled to a varying
extent by pancreatic enzyme supplements. None
had severe liver disease. Nevertheless, all but three
patients had low serum concentrations of vitamin E
and in four the vitamin was undetectable. When vit-
amin E status was expressed as the serum vitamin
E/cholesterol ratio, six patients fell into the normal
range. This difference reflects the mild hypocholes-
terolaemia observed in the patient group which
results from fat malabsorption. The neurologically
abnormal patient had greatly reduced serum vitamin
E concentrations but no definite correlation could
be obtained between clinical neurological dysfunc-
tion and vitamin E status in the series as a whole.

The prominent central sensory axonopathy which
underlies the spinocerebellar syndrome associated
with vitamin E deficiency can be demonstrated by the
use of SSEPs in symptomatic patients, showing
delay in conduction between the cervical spinal
cord and the sensory cortex.\(^2\)\(^3\)\(^4\)\(^\text{\textsuperscript{17}}\) SSEPs were normal in all
the asymptomatic cases studied here, including the
one with mild but definite clinical abnormalities sug-
gestig posterior column dysfunction. This observa-
tion implies that the SSEP is not sensitive enough to
reflect minor, but clinically significant, degenerative
changes in the posterior columns in this syndrome.

The finding of ERG abnormalities in two cases
indicates the presence of subclinical retinal dysfunc-
tion, the aetiology of which is not clear. Serum vita-
mn E concentrations were not excessively low com-
pared to the group as a whole, and vitamin A con-
centrations were normal. Experimental data suggest
that either vitamin E or A deficiency can result in
retinal degeneration, and that combined deficiency
has a synergistic harmful effect on photoreceptor
cells, probably because vitamin E deficiency accentu-
ates light induced peroxidative retinal damage and
increases oxidative destruction of stored vitamin
A.\(^18\)\(^19\)\(^20\)

A possible relationship between retinal dysfunc-
tion and a deficiency of vitamin E and/or vitamin A
is also evident from clinical studies in patients with
severe fat malabsorption. Clinical and electro-
retinographic improvement has been described
after the administration of vitamin A alone to
patients with retinopathy associated with
abetalipoproteinaemia.\(^21\)\(^22\) However, a child with
abetalipoproteinaemia developed a retinopathy
despite having normal serum concentrations of vit-
amin A.\(^23\) Since commencing vitamin E supplemen-
tation 17 years ago her retinopathy has not progres-
sed.\(^24\) Several of the patients with vitamin E defi-
ciency secondary to chronic cholestasis reported by
Alvarez and colleagues\(^25\) had clinical and elec-
trophysiological evidence of retinal dysfunction in
the presence of normal serum vitamin A concentra-
tions.

It is possible that the VEP abnormalities observed
in one of the patients in this study, and also that
described in the case report, were secondary to reti-
nal dysfunction, but delayed VEP latencies have
recently been reported in a patient with cystic
fibrosis and a spinocerebellar syndrome in whom the
ERG was normal.\(^25\) These reverted to normal after
two months of vitamin E therapy. As far as we are
aware, the optic nerves have not been examined
pathologically in either human or experimental vit-
amin E deficiency. Optic neuropathy has been attrib-
uted to prolonged chloramphenicol therapy in
patients with cystic fibrosis, and it is possible that
this predisposition is related to vitamin deficien-
cies.\(^26\) None of the patients in the present study had
received prolonged chloramphenicol therapy.

Neurological abnormalities have been found in
1.5% and 2.5% of patients in two previous series of
cases of cystic fibrosis.\(^27\)\(^28\) Although the studies are
not directly comparable because of different selec-
tion and assessment criteria, one of the present
series of 29 was found to have definite clinical
abnormalities and two were abnormal on
neurophysiological grounds.

The relationship between serum vitamin E con-
centrations and these findings is not a simple one, as
has been observed previously.\(^28\) It is reasonable to
suggest that the development of a spinocerebellar
syndrome and severe vitamin E deficiency are caus-
ally related as a number of deficient patients with
ataxic syndromes have improved objectively after
vitamin E supplementation.\textsuperscript{1,2} Vitamin E deficiency needs to be prolonged before neurological dysfunction develops. Patients with abetalipoproteinaemia have undetectable serum concentrations of vitamin E from birth, but do not usually have neurological symptoms until the second decade of life.\textsuperscript{29} Neuropathological studies have demonstrated that there is a high incidence of axonal degeneration in the rostral parts of the posterior columns in the spinal cord of patients with cystic fibrosis, a lesion characteristic of vitamin E deficiency.\textsuperscript{30,31} The incidence of this finding increases with age in untreated patients but appears to have fallen since the introduction of vitamin E supplementation in cystic fibrosis in the United States.\textsuperscript{30}

In view of the uncertainty about the degree of vitamin E deficiency required to cause neurological dysfunction in cystic fibrosis, it seems prudent to suggest that serum vitamin E concentrations are measured regularly in all patients, and that these are maintained within the normal range by means of appropriate supplementation. We have treated patients with uncomplicated cystic fibrosis with a fat soluble oral preparation of alpha tocopherol acetate (Ephynal—Roche) and found that normal serum vitamin E concentrations could generally be achieved after one month on a dose of 10 mg/kg/day. Thereafter a lower dose of 200 mg/day appeared sufficient to maintain concentrations within the normal range (Muller \textit{et al}, unpublished observations).

A policy of supplementing deficit patients would be more practical than performing regular detailed neurological assessments and starting treatment only when neurological dysfunction becomes clinically evident. It would have the important advantage of preventing neurological disability which is likely to become more prevalent as the population of patients with cystic fibrosis grows older owing to improved medical management.

We thank Drs JC Batten and R Knight for allowing us to study patients under their care, and Dr C Kemp (Institute of Visual Science, London) for performing the vitamin A assays. Dr Muller thanks Hoffmann-La Roche for their support and Dr Stead was supported by the Augustus and Frances Newman Foundation.

References
\begin{itemize}
\item \textsuperscript{1} Muller DPR, Lloyd JK, Wolff OH. Vitamin E and neurological function. \textit{Lancet} 1983;i:225-8.
\item \textsuperscript{4} Elias E, Muller DPR, Scott J. Spinocerebellar disorders in association with cystic fibrosis or chronic childhood cholestatis and virtually undetectable serum concentrations of vitamin E. \textit{Lancet} 1981;i:1319-21.
\item \textsuperscript{5} Bye AME, Muller DPR, Wilson J, Wright VM, Mearns MB. Symptomatic vitamin E deficiency in a patient of 10 years with cystic fibrosis. \textit{Arch Dis Child} 1985;60:162-4.
\item \textsuperscript{10} Muller DPR, Harries JT, Lloyd JK. The relative importance of the factors involved in the absorption of vitamin E in children. \textit{Gut} 1974;15:966-71.
\item \textsuperscript{12} Bieri JG, Tolliver TBS, Catignani GL. Simultaneous detection of alpha tocopherol and retinol in plasma or red cells by high performance liquid chromatography. \textit{Am J Clin Nutr} 1979;32:2143-9.
\item \textsuperscript{13} Farrell PM, Levine SL, Murphy MD, Adam AJ. Plasma tocopherol levels and tocopherol-lipid relationships in a normal population of children as compared to healthy adults. \textit{Am J Clin Nutr} 1978;31:1720-6.
\item \textsuperscript{16} Harries JT, Muller DPR. Absorption of vitamin E in children with biliary obstruction. \textit{Gut} 1971;12:579-84.
\item \textsuperscript{17} Harding AE, Jones S, Booth IW, Ellis CJK, Muller DPR. Spinocerebellar degeneration related to a selective defect of vitamin E absorption. \textit{N Engl Med J} 1985 (in press).
\item \textsuperscript{18} Hayes KC. Retinal degeneration in monkeys induced by deficiencies of vitamin E or A. \textit{Invest Ophthalmol Vis
Willison, Muller, Matthews, Jones, Kriss, Stead, Hodson, Harding


24 Muller DPR, Lloyd JK. Effect of large oral doses of vitamin E on the neurological sequelae of patients with abetalipoproteinemia. Ann NY Acad Sci 1982;393:133–44.


